New Approaches toward Anti-HIV Chemotherapy

This publication has 81 references indexed in Scilit:

• Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins
  Journal of Virology, 2004
• Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
  New England Journal of Medicine, 2004
• Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients
  Antimicrobial Agents and Chemotherapy, 2003
• Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Individuals for Whom Interferon‐α and Lamivudine Therapy Have Failed
  The Journal of Infectious Diseases, 2002
• HIV-1 integrase and RNase H activities as therapeutic targets
  Emerging Therapeutic Targets, 2002
• 1,2,4-Triazole Derivatives Inhibiting the Human Immunodeficiency Virus Type 1 (HIV-1) in vitro
  Helvetica Chimica Acta, 2002
• The Catalytic Activity of Protein Disulfide Isomerase Is Involved in Human Immunodeficiency Virus Envelope–Mediated Membrane Fusion after CD4 Cell Binding
  The Journal of Infectious Diseases, 2001
• Once‐Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Human Immunodeficiency Virus–Infected Patients
  The Journal of Infectious Diseases, 2000
• Antiviral Activity of 2′-Deoxy-3′-Oxa-4′-Thiocytidine (BCH-10652) against Lamivudine-Resistant Human Immunodeficiency Virus Type 1 in SCID-hu Thy/Liv Mice
  Antimicrobial Agents and Chemotherapy, 2000
• Potent and selective anti-HTLV-IIILAV activity of 2′,3′-dideoxycytidinene, the 2′,3′-unsaturated derivative of 2′,3′-dideoxycytidine
  Biochemical and Biophysical Research Communications, 1986